The cancer therapeutics market size is expected to reach US$ 5,31,538.02 million by 2031 from US$ 2,30,423.56 million in 2024. The market is estimated to record a CAGR of 12.8% from 2025 to 2031.
Executive Summary and Global Market Analysis
The global cancer therapeutics market is experiencing significant expansion, propelled by the increasing burden of breast and lung cancer and substantial investments in oncology research. Cancer therapeutics encompasses a wide array of treatments focused on managing or curing cancer. Common treatment modalities include chemotherapy, radiation, immunotherapy, targeted therapy, hormone therapy, surgery, and stem cell therapy. These strategies primarily aim to eliminate or control cancer cells, alleviate symptoms, and enhance patient survival. Depending on the cancer type, stage, and the patient’s overall health, a combination of these treatments is often employed to maximize effectiveness.
Cancer Therapeutics Market Segmentation Analysis
The analysis of the cancer therapeutics market is derived from key segments: therapy type, indication, and distribution channel.
By therapy type, the market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. Chemotherapy dominated the market in 2024.
In terms of indications, the market covers blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. Lung cancer held the largest market share in 2024.
By distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online stores. Hospital pharmacies held the largest share of the market in 2024.
Download our Sample PDF Report
@ https://www.businessmarketinsights.com/sample/BMIRE00031299
Cancer Therapeutics Market Drivers and Opportunities
As per the World Health Organization, approximately 1 in 6 deaths worldwide are attributed to various types of cancer. In 2022, there were roughly 20 million new cancer cases and 9.7 million deaths, with the burden projected to increase by about 77% by 2050, further straining health systems and communities. The American Cancer Society reports that 5–10% of all cancers are inherited. Numerous genes predisposing individuals to cancer have been identified; for instance, mutations in BRCA1 and BRCA2 genes increase the risk of breast, ovarian, and prostate cancer. Breast cancer is deemed the most prevalent cancer among women globally, with continuously rising incidence due to environmental impact, genetic susceptibility, hormone imbalances, and lifestyle changes. It also remains one of the most prevalent cancers in the U.S.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
